Literature DB >> 521057

Activation of mouse complement by different classes of mouse antibody.

G G Klaus, M B Pepys, K Kitajima, B A Askonas.   

Abstract

The capacity of mouse IgM, IgGl, IgG2 and IgA anti-dinitrophenyl (DNP) antibodies to activate mouse or guinea-pig complement was studied, using a sensitive haemolytic assay and two-dimensional immunoelectrophoresis to detect cleavage of mouse C3. Three monoclonal IgM antibodies, and a heterogeneous IgM fraction, lysed trinitrophenylated erythrocytes in the presence of guinea-pig C, but failed to produce lysis in the presence of mouse C. and only activated mouse C3 very inefficiently. A monoclonal IgGl antibody did not produce haemolysis in the presence of guinea-pig or mouse C, but cleaved mouse C3 via the alternative pathway. Two IgA myeloma proteins (M315 and M460) had similar properties. A heterogeneous IgG2 antibody fraction produced haemolysis in the presence of both mouse and guinea-pig C, and was shown to activate both the classical and alternative pathways of mouse C.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 521057      PMCID： PMC1457877     

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  20 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  Solubilization of IgA immune precipitates by complement.

Authors:  G W Miller
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

3.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

4.  A sensitive haemolytic assay of mouse complement.

Authors:  J H Berden; J F Hagemann; R A Koene
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

Review 5.  Biological activities of immunoglobulins of different classes and subclasses.

Authors:  H L Spiegelberg
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

6.  A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway.

Authors:  J E May; M M Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

7.  Evidence that bovine conglutinin reacts with an early product of C3b degradation, and an improved conglutination assay.

Authors:  W D Linscott; R Ranken; R P Triglia
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

8.  Generation of memory cells. III. Antibody class requirements for the generation of B-memory cells by antigen--antibody complexes.

Authors:  G G Klaus
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

9.  A microassay for the determination of hemolytic complement activity in mouse serum.

Authors:  B S Andrews; A N Theofilopoulos
Journal:  J Immunol Methods       Date:  1978       Impact factor: 2.303

10.  The effect of complement on the ingestion of soluble antigen-antibody complexes and IgM aggregates by mouse peritoneal macrophages.

Authors:  J L van Snick; P L Masson
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307
View more
  65 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

4.  Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Authors:  Roudaina Nasser; Mireia Pelegrin; Henri-Alexandre Michaud; Marc Plays; Marc Piechaczyk; Laurent Gros
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

5.  Natural serum antibodies which bind to damaged erythroblasts: isotypes and light-chain composition.

Authors:  E Wiener; S N Wickramasinghe
Journal:  Int J Exp Pathol       Date:  1990-12       Impact factor: 1.925

6.  Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

8.  Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles.

Authors:  Yeu-Chun Kim; Fu-Shi Quan; Dae-Goon Yoo; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  Protection of mice against Mycoplasma pulmonis infection using purified mouse immunoglobulins: comparison between protective effect and biological properties of immunoglobulin classes.

Authors:  G Taylor; C J Howard
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

10.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.